Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tiziana Life SciencesTLSA -0.45%23 Debt-to-Equity is 8.77 as of Dec. 2025, which is 29133% above its 10-year median of 0.03. GuruFocus rates TLSA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 965 Biotechnology companies, Tiziana Life Sciences ranks worse than 98.86% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Tiziana Life Sciences's Debt-to-Equity or its related term are showing as below:
TLSA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.15 Med: 0.03 Max: 8.77
Current: 8.77
During the past 13 years, the highest Debt-to-Equity Ratio of Tiziana Life Sciences was 8.77. The lowest was -0.15. And the median was 0.03.
TLSA's Debt-to-Equity is ranked worse than 98.86% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs TLSA: 8.77
Tiziana Life Sciences (NAS:TLSA) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Tiziana Life Sciences Debt-to-Equity Related Terms
Tiziana Life Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Tiziana Life Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLSA vs SPRB, MIST, TNYA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Tiziana Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tiziana Life Sciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Tiziana Life Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tiziana Life Sciences (TLSA) has a Debt-to-Equity of 8.77 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tiziana Life Sciences and its competitors. This is 29133% above median its historical median of 0.03. According to the industry distribution chart, Tiziana Life Sciences ranks #954 out of 965 companies in the Biotechnology industry, placing it in the top 98.9%.
Is Tiziana Life Sciences' Debt-to-Equity too high?
Tiziana Life Sciences' current Debt-to-Equity of 8.77 is 29133% above median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Tiziana Life Sciences' value of 8.77 is 5381.3% above this industry median. Based on the distribution chart, Tiziana Life Sciences ranks #954 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tiziana Life Sciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Tiziana Life Sciences' Debt-to-Equity compare to SPRB and MIST?
According to the Biotechnology industry distribution chart, Tiziana Life Sciences ranks #954 out of 965 companies for Debt-to-Equity. This places Tiziana Life Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Tiziana Life Sciences' value of 8.77 is 5381.3% above this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Tiziana Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tiziana Life Sciences's current Debt-to-Equity of 8.77 is 5381.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tiziana Life Sciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tiziana Life Sciences's current Debt-to-Equity is 8.77, which is 29133% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tiziana Life Sciences stock overvalued right now?
Tiziana Life Sciences (TLSA) has a current Debt-to-Equity of 8.77. The current Debt-to-Equity is 8.77, which is 29133% above median its 10-year median of 0.03 and 5381.3% above the Biotechnology industry median of 0.16. Tiziana Life Sciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Tiziana Life Sciences (TLSA), the current Debt-to-Equity is 8.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
23GF Score
Get the complete analysis for TLSA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSA has been successfully added to your 
